gressive disease affecting almost exclusively women that is seen in both patients with tuberous sclerosis complex (TSC) and those without TSC, the latter termed sporadic LAM (S-LAM) (1) (2) (3) (4) (5) . LAM is characterized by infiltration of the lung parenchyma by neoplastic spindle-shaped cells with combined smooth muscle and melanocytic differentiation, and is associated with both extensive involvement of lymphatic channels by similar cells in nearly all cases, and occurrence of renal angiomyolipoma in 30 to 50% of S-LAM cases (3) . Past seminal publications identified mutations and loss of heterozygosity (LOH) in TSC2 in pulmonary LAM cells of four S-LAM patients who had angiomyolipomas with known mutations (6) , and in two of five S-LAM patients (7) . Other studies have shown that TSC2 mutations are seen in cultured LAM cells (8) , and that TSC2 LOH is seen in LAM cells isolated from blood, urine, chylous fluid, and bronchoalveolar lavage fluid in 50 to 90% of S-LAM patients (9, 10) . Some of the results of this study have been previously reported in the form of abstracts (11, 12) .
We searched for TSC2 mutations in 10 S-LAM patients that had lung transplant using a combination of laser capture microdissection (LCM) and next-generation sequencing (NGS) (see online supplement). Examination of formalinfixed paraffin-embedded sections showed classic features of LAM, with multiple cysts and disseminated LAM nodules, the cells of which were smooth muscle actin (SMA) and HMB45 positive (Figures E8A-E8G in the online supplement). LCM guided by SMA immunohistochemistry was performed on frozen sections to collect LAM cells from nodules ( Figure E1 ) and avoid inclusion of lymphatic channels, lymphocytes, and other cell types ( Figures E3 and E4 ). After DNA extraction and amplification, NGS was performed using either the 454 or Illumina platforms (Reference 13 and online supplement). High read depth was achieved across the coding region of TSC2 (median, 486; .200 in 96% of exons), enabling detection of low-frequency sequence variants. Nine different pathogenic sequence variants were detected in TSC2 in eight different sporadic LAM samples, at frequencies ranging from 4 to 60% (Table 1) , with most seen at This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org a frequency less than 20%. All were verified by Sanger or SNaPshot analysis on unamplified DNA ( Figures E6 and E7 ). Four samples showed evidence of two-hit inactivation in TSC2, three of them with a mutation and LOH, and one with two point mutations. The four cases without LOH all had low allele fractions for mutation in TSC2 (<16%), making detection of LOH difficult. The two LAM samples in which no TSC2 mutation was identified also showed no mutation in TSC1 by NGS sequencing. Significantly, in one of these cases, over 90% of LAM cells were positive for HMB45 (case 9023) ( Figure  E8B ), and in the other, the patient had a concomitant renal angiomyolipoma, providing additional evidence of S-LAM (1, 2).
HMB45
1 cells in LAM sections have relatively low PCNA expression, suggesting that they are less proliferative than HMB45 2 cells (14) . Although some types of inactivating mutations are missed by exonic sequencing, immunohistochemistry for TSC2 (tuberin) and TSC1 (hamartin) on the two cases without defined mutations showed strong expression of each protein, whereas little or no expression of either was seen in a control case with two mutations in TSC2 (Figure 1 and Figure E10 ). Furthermore, the two cases without TSC1/TSC2 mutation showed no expression of phospho-S6 kinase by immunohistochemistry, in contrast to cases in which biallelic TSC2 mutations were identified ( Figures 1G-1I ). This suggests that mechanistic target of rapamycin complex 1 (mTORC1) was not activated in the LAM nodules of these two patients, consistent with normal TSC1/TSC2 function and mTOR regulation.
The occurrence of TSC2 mutations at relatively low frequency, or not at all, in these LAM samples is surprising. As shown here and elsewhere (13) , NGS has the capability to detect mutations that are present at a very low allelic fraction, 1% or lower, enabling high sensitivity analyses as performed here. High sample contamination with non-LAM cells seems unlikely given our efforts at histological purification of the cells collected by LCM, the identification of mutations at high frequency in some cases, and the detection of a low-and a high-frequency mutation in one case. It is possible that TSC2 mutations occur in a subset of LAM cells, after other unknown initiating events, and are not the primary driver of LAM development, or TSC2-mutant cells recruit stromal cells to adopt an SMA-positive phenotype. In addition, the two cases without TSC1 or TSC2 mutations identified also suggest that alternative genetic mechanisms may be operative in some cases of LAM.
Recently the Multicenter International LAM Efficacy of Sirolimus (MILES) trial demonstrated that rapamycin (sirolimus), an mTORC1 inhibitor that blocks the pathway activated by loss of tuberin (15), was an effective therapy for treatment of LAM (16) . However, it is notable that continuing FEV 1 decline was seen in 50% of patients on rapamycin therapy. It is possible that some of these nonresponders do not have loss of TSC2 with activation of mTORC1 as a fundamental pathogenic mechanism for LAM development, consistent with our data. were used at 1:100 dilution according to standard protocols used in diagnostic pathology lab. The slides were examined and interpreted by 2 independent pathologists (E. H. and L.S.).
Next generation sequencing (NGS)

NGS
Whole genome amplified DNA (WGA-DNA) from LAM lesions was analyzed for mutations in TSC1 and TSC2 using deep sequencing by the 454 technique (Roche Applied Sciences, Indianapolis, IN), as described in detail elsewhere (1) . In brief, exons were amplified using specially designed oligonucleotide primers, consisting of a 15-28 bp target-specific sequence at their 3′ end, and a common 19 bp region that was used in subsequent clonal amplification and sequencing reactions at their 5′ end. Amplicons ranged in size from 135 to 393 bp. PCR was performed on 10-25 ng of WGA-DNA using the FastStart High Fidelity PCR System (Roche Applied Sciences) and standard thermocycling conditions. Amplicon products were purified, quantified, and pooled at an equimolar ratio for sequencing. Single molecules were clonally amplified on beads in an oil emulsion; beads were then isolated and loaded into picotiter plates for pyrosequencing (2, 3) . Individual patient samples were multiplexed in sets of 8, and sequencing was performed on the Genome Sequencer FLX system (Roche Applied Sciences). The median and mean number of reads was 486 and 506, respectively, at the coding and splice site nucleotides of TSC2. 95.5% of amplicons had a read depth >200, and 98.6% had a read depth >100.
454 sequence data was analyzed using Amplicon Variant Analysis (AVA; Roche Applied Sciences) software to identify sequence variants in TSC1 and TSC2. As described previously (1), many low-frequency sequence variants are detected in 454 analyses, and we eliminated from further consideration those variants that were: (1) detected in >1 sample at low frequency; (2) detected in <5 sequencing reads; and (3) detected only in poor quality reads by manual review.
Illumina NGS
Next generation sequencing of most of the genomic extent of TSC2 was performed on the Illumina GAIIx or HiSeq2000 (Illumina, San Diego, CA). Long-range PCR was performed on LAM WGA-DNA using 4 primer sets that cover all of the coding exons and most of the intronic sequence of TSC2, a total of 34,770 nt. Amplicons were then purified were minimally amplified, purified using AMPure beads, minimally reamplified with primers encoding an index sequence (Illumina), and purified using AMPure beads.
Libraries from different samples with different indices were then mixed at an equimolar ratio and sequenced on an Illumina GAIIx or HiSeq2000 sequencer for 50-75 nt reads.
Sequencing data output was analyzed using a combination of standard tools and custom software to enable detection of sequence variants at >1% frequency. The primary data were deconvoluted using the index sequences to individual sample files and converted to FASTQ format, aligned to the human genome using bwa-0. those from other samples, including controls, to exclude artifacts derived from the sequencing process. All variants seen at a frequency of >1% more than that seen in other samples were directly reviewed using the Integrative Genomics Viewer (4) (IGV;
www.broadinstitute.org/software/igv/) to help confirm bona fide variant calls and to exclude sequencing artifacts. A median read depth for all nucleotides of the TSC2 coding exons and nearby introns of >2,000 was achieved by Illumina NGS, and >94% of these nucleotides were covered at a read depth of >1,000.
Validation of NGS findings
Single-nucleotide variants and indels that were identified as novel and/or of possible significance by either 454 or Illumina NGS were confirmed by secondary analysis of the initial non-WGA DNA sample, using Sanger bidirectional sequencing in the case of variants seen at > 20% allele ratio and SNaPshot analysis for those seen at <20% allele ratio. SNaPshot analysis was performed as described elsewhere (1). Primer extension products were analyzed on an ABI 3100 sequencer (Applied Biosystems, Carlsbad, CA), and the proportion of alleles was quantified using GeneMapper 
